GO:0097039 protein linear polyubiquitination: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0097039 protein linear polyubiquitination describes the addition of a linear ubiquitin polymer, linked via the amino-terminal methionine (M1) of one ubiquitin to the carboxy-terminal glycine (G76) of the next, to a target protein.
• The process is best known for its role in NF-kappaB activation, where linear ubiquitin chains on NEMO and other components drive inflammatory and immune signaling.
• Linear polyubiquitination regulates cell death pathways, including apoptosis, necroptosis, and pyroptosis, and is implicated in cancer, autoinflammation, and infection.
• The process is highly regulated and reversible, with dedicated enzymes and deubiquitinases controlling chain assembly and disassembly.
• Dysregulated linear polyubiquitination contributes to diseases such as Kawasaki disease, where it stabilizes NFAT1 and facilitates NFAT1 signaling.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) are powerful tools to dissect the causal roles of linear polyubiquitination genes in health and disease.
Description
Protein linear polyubiquitination (GO:0097039) is a specialized post-translational modification in which a linear polymer of ubiquitin is attached to a target protein. Unlike canonical ubiquitin chains that form through lysine residues, this polymer is generated by the conjugation of the amino-terminal methionine (M1) of one ubiquitin molecule to the carboxy-terminal glycine (G76) of the next, producing a head-to-tail linkage often called the M1 linkage. This unique architecture confers distinct structural and signaling properties that are increasingly recognized as central to immune regulation and cell fate decisions. Since its discovery, linear polyubiquitination has emerged as a critical regulator of the NF-kappaB pathway, where it serves as a scaffold for the recruitment of kinase complexes and adaptor proteins. Beyond immunity, it controls cell death, angiogenesis, and host-pathogen interactions, and its dysregulation is linked to inflammatory diseases, cancer, and infection. Understanding the molecular players and regulatory mechanisms of linear polyubiquitination is therefore essential for researchers in immunology, oncology, and cell biology. This article provides a comprehensive overview of GO:0097039, covering its definition, biological significance, core mechanisms, key genes, disease associations, and state-of-the-art research methods, including CRISPR-based approaches for functional validation.
protein linear polyubiquitination At A Glance
| GO ID | GO:0097039 |
|---|---|
| GO term | protein linear polyubiquitination |
| Ontology | biological_process |
| Synonym | M1 linkage |
| Definition | A protein ubiquitination process in which a linear polymer of ubiquitin, formed by the amino-terminal methionine (M1) of one ubiquitin molecule and by the carboxy-terminal glycine (G76) of the next, is added to a protein. |
| Major function | Regulation of NF-kappaB signaling, immunity, cell death, and inflammation |
| Key enzymes | Linear ubiquitin chain assembly complex (LUBAC) and associated E2 enzymes |
| Reversibility | Regulated by deubiquitinases such as OTULIN and CYLD |
| Disease relevance | Cancer, autoinflammatory diseases, infection, and Kawasaki disease |
What Is GO:0097039?
Protein linear polyubiquitination (GO:0097039) is a biological process in which a linear polymer of ubiquitin, formed by the amino-terminal methionine (M1) of one ubiquitin molecule and the carboxy-terminal glycine (G76) of the next, is covalently attached to a target protein. This modification, also known as M1-linked polyubiquitination, differs from other ubiquitin linkages because it generates a linear chain rather than a branched or lysine-linked structure.
Why Is protein linear polyubiquitination Important in Cell Biology?
Protein linear polyubiquitination is a pivotal regulatory mechanism that controls fundamental cellular processes, particularly immune signaling and cell survival. Its unique M1 linkage provides a specific docking platform for NF-kappaB signaling components, and its dysregulation is directly implicated in inflammatory disorders, cancer, and infectious diseases. As a result, understanding this process offers insights into disease pathogenesis and potential therapeutic targets.
• Controls NF-kappaB activation, a master regulator of inflammation and immunity.
• Regulates cell death pathways, including apoptosis and necroptosis.
• Modulates angiogenesis through fine-tuning of ALK1 signaling.
• Plays a role in host defense against pathogens such as KSHV.
• Contributes to the pathogenesis of Kawasaki disease via NFAT1 stabilization.
• Involved in lysosomal damage response and local NF-kappaB activation.
• Provides a unique structural platform for signal transduction.
• Represents a potential therapeutic target for inflammatory diseases and cancer.
• Essential for immune homeostasis and prevention of autoinflammation.
• Offers a paradigm for studying non-canonical ubiquitin linkages.
What Happens During protein linear polyubiquitination?
Initiation and chain assembly
In simple terms: First, a linear ubiquitin chain is built on a target protein by a dedicated enzyme complex.
Linear polyubiquitination is initiated by the linear ubiquitin chain assembly complex (LUBAC), which consists of HOIP, HOIL-1L, and SHARPIN. LUBAC catalyzes the formation of M1-linked ubiquitin chains on substrate proteins, such as NEMO, by linking the C-terminal glycine of one ubiquitin to the N-terminal methionine of the next. This process requires the E2 enzyme UBE2L3 and is tightly regulated to prevent uncontrolled signaling.
Substrate recognition and modification
In simple terms: The chain is attached to specific target proteins, often in response to cellular signals.
Substrate specificity is determined by interactions between LUBAC and target proteins. For example, NEMO is a well-characterized substrate where linear ubiquitination induces a conformational change that facilitates NF-kappaB activation. Other substrates include components of the NF-kappaB pathway, such as RIPK1, and proteins involved in cell death and immune signaling.
Signal transduction and downstream effects
In simple terms: Once attached, the linear ubiquitin chain acts as a scaffold to recruit signaling proteins.
Linear ubiquitin chains serve as binding platforms for proteins containing ubiquitin-binding domains, such as NEMO, TAB2/3, and IKK complexes. This recruitment leads to the activation of NF-kappaB and MAPK pathways, driving gene expression programs that control inflammation, survival, and proliferation. Additionally, linear ubiquitination at damaged lysosomes induces local NF-kappaB activation to promote cell survival.
Reversal and regulation
In simple terms: The modification is reversible, and enzymes called deubiquitinases remove the chains to terminate signaling.
Deubiquitinases such as OTULIN and CYLD specifically cleave M1-linked ubiquitin chains, thereby negatively regulating linear polyubiquitination. This reversibility is crucial for preventing excessive inflammation and maintaining immune homeostasis. Dysregulation of these enzymes can lead to autoinflammatory diseases and cancer.
Key Genes Involved in GO:0097039 protein linear polyubiquitination
The following genes and proteins are central to the process of protein linear polyubiquitination, either as enzymes, substrates, or regulators.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HOIP (RNF31) | Catalytic subunit of LUBAC, forms linear ubiquitin chains | Core enzyme for linear polyubiquitination; knockout models show defective NF-kappaB signaling |
| HOIL-1L (RBCK1) | Accessory subunit of LUBAC, stabilizes complex | Mutations linked to autoinflammation and immunodeficiency |
| SHARPIN | Accessory subunit of LUBAC, regulates complex activity | Deficiency causes chronic proliferative dermatitis in mice |
| NEMO (IKBKG) | Substrate and adaptor, binds linear ubiquitin chains | Conformational change upon linear ubiquitination activates NF-kappaB |
| RIPK1 | Substrate, involved in cell death and NF-kappaB signaling | Linear ubiquitination modulates RIPK1-dependent apoptosis and necroptosis |
| OTULIN | Deubiquitinase, removes M1-linked chains | Negative regulator; mutations cause autoinflammatory syndrome |
| CYLD | Deubiquitinase, removes M1-linked chains | Tumor suppressor; regulates NF-kappaB and cell death |
| NFAT1 (NFATC2) | Substrate, stabilized by linear ubiquitination | Implicated in Kawasaki disease pathogenesis |
| ALK1 (ACVRL1) | Substrate, regulated by linear polyubiquitination | Controls angiogenesis; fine-tuning by linear ubiquitination |
| KSHV RTA | Viral protein, targeted by linear ubiquitination | Regulates KSHV replication and infection |
| UBE2L3 | E2 enzyme for LUBAC | Required for linear ubiquitin chain assembly |
| TAB2/TAB3 | Ubiquitin-binding adaptors | Recruit downstream kinases in NF-kappaB pathway |
| IKKalpha/beta | Kinases activated downstream | Phosphorylate IkappaB and activate NF-kappaB |
| A20 (TNFAIP3) | Deubiquitinase and ubiquitin ligase | Regulates linear ubiquitination and NF-kappaB |
| LUBAC complex | Multiprotein complex | Central enzyme machinery for linear polyubiquitination |
How Is protein linear polyubiquitination Regulated?
Linear polyubiquitination is tightly regulated at multiple levels. The activity of LUBAC is controlled by its subunit composition, post-translational modifications, and interacting proteins. Deubiquitinases such as OTULIN and CYLD counteract LUBAC activity by cleaving M1-linked chains, ensuring signal termination. Additionally, linear ubiquitination is dynamically regulated during cellular stress, such as lysosomal damage, where local activation of NF-kappaB occurs. The process is also modulated by viral proteins, as seen with KSHV RTA, which exploits linear ubiquitination to control infection.
protein linear polyubiquitination and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HOIP (RNF31) | Cancer, autoinflammation | Knockout cell lines, mouse models |
| OTULIN | Autoinflammatory syndrome | Point mutation knock-in mice |
| NFAT1 (NFATC2) | Kawasaki disease | Overexpression and knockout cell models |
| KSHV RTA | KSHV infection | Viral infection models with knockout cells |
| ALK1 (ACVRL1) | Angiogenesis disorders | Endothelial cell knockout and knock-in |
Linear polyubiquitination in cancer and inflammation
Dysregulated linear polyubiquitination is implicated in cancer through its control of NF-kappaB, a transcription factor that promotes cell survival and proliferation. Mutations in LUBAC components or deubiquitinases can lead to constitutive NF-kappaB activation, contributing to tumorigenesis. Inflammatory diseases, such as autoinflammatory syndromes, are also linked to defects in linear ubiquitination, highlighting its role in immune homeostasis.
Role in Kawasaki disease
Linear ubiquitination stabilizes NFAT1, a transcription factor involved in immune responses, and facilitates NFAT1 signaling in Kawasaki disease, a vasculitis of childhood. This suggests that targeting linear ubiquitination could be a therapeutic strategy for Kawasaki disease.
Linear polyubiquitination in infection and host defense
Pathogens such as KSHV manipulate linear ubiquitination to promote their replication. The viral protein RTA is regulated by linear ubiquitination, which controls KSHV infection. Conversely, linear ubiquitination is part of host defense mechanisms against pathogens, underscoring its dual role in infection.
Lysosomal damage and cell survival
Linear ubiquitination at damaged lysosomes induces local NF-kappaB activation, which promotes cell survival. This pathway is critical for cellular responses to lysosomal stress and may be relevant to neurodegenerative diseases where lysosomal dysfunction occurs.
From protein linear polyubiquitination-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate linear polyubiquitination? | Knockout cell lines (e.g., HOIP KO) |
| What is the effect of a specific point mutation in a ligase? | Point mutation knock-in via CRISPR |
| How does a disease-associated mutation affect NF-kappaB signaling? | Knock-in of mutant allele in cell lines |
| Where does linear ubiquitination occur in cells? | Tagged knock-in of ubiquitin or substrate |
| Can overexpression of a deubiquitinase rescue a phenotype? | Overexpression cell models |
| What is the role of linear ubiquitination in viral infection? | Knockout cells infected with KSHV |
How to Study the protein linear polyubiquitination Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Immunoblotting with anti-linear ubiquitin | Presence of M1-linked chains | Detection in cell lysates |
| Mass spectrometry | Chain linkage and substrate identification | Proteomic profiling |
| Luciferase reporter assay | NF-kappaB transcriptional activity | Functional validation |
| CRISPR knockout screening | Genes regulating linear ubiquitination | Discovery of novel regulators |
| Immunofluorescence | Subcellular localization | Visualization of linear ubiquitination |
| Co-immunoprecipitation | Protein-protein interactions | Complex assembly studies |
| Quantitative PCR | Gene expression changes | Downstream target analysis |
Detection of linear ubiquitin chains
Linear ubiquitin chains can be detected using specific antibodies or mass spectrometry. Immunoprecipitation followed by immunoblotting with anti-linear ubiquitin antibodies is commonly used. Mass spectrometry can identify M1-linked chains and their substrates.
Functional assays for NF-kappaB activation
NF-kappaB activation is measured using luciferase reporter assays, electrophoretic mobility shift assays (EMSA), or immunoblotting for phosphorylated IkappaB and p65. These assays are used to assess the impact of linear polyubiquitination on signaling.
CRISPR screening for regulators
Genome-wide CRISPR knockout screens can identify genes that regulate linear polyubiquitination and NF-kappaB signaling. Such screens have revealed novel components of the pathway and potential therapeutic targets.
Imaging and localization studies
Fluorescence microscopy with tagged ubiquitin or substrate proteins can visualize the localization of linear ubiquitination in cells, such as at damaged lysosomes or within signaling complexes.
How CRISPR Can Be Used to Study GO:0097039 protein linear polyubiquitination
Knockout
CRISPR knockout of genes such as HOIP, HOIL-1L, or SHARPIN abolishes linear polyubiquitination, leading to defective NF-kappaB activation. These models are essential for studying the loss-of-function effects on immunity and cell death.
Point Mutation
Point mutations can be introduced into catalytic residues of LUBAC components or deubiquitinases to dissect their enzymatic activity. For example, mutation of the catalytic cysteine in HOIP prevents linear chain formation, allowing separation of ligase-dependent and independent functions.
Knock-in
Knock-in of disease-associated mutations, such as those in OTULIN, can model autoinflammatory syndromes. Tagged knock-in of ubiquitin or substrates enables tracking of linear ubiquitination dynamics in live cells.
Overexpression
Overexpression of LUBAC components or deubiquitinases can amplify or suppress linear polyubiquitination, respectively. This approach is useful for gain-of-function studies and for testing therapeutic candidates.
How EDITGENE Supports protein linear polyubiquitination Research
Researchers studying protein linear polyubiquitination-related genes often need to determine whether a candidate gene is causally involved in the pathway or merely correlated with its activity. CRISPR-based models provide a robust way to establish causality by precisely manipulating the genome.
Contact EDITGENE today to design your custom CRISPR model for protein linear polyubiquitination research.
Frequently Asked Questions About protein linear polyubiquitination
What is protein linear polyubiquitination?
Protein linear polyubiquitination (GO:0097039) is a process where a linear chain of ubiquitin molecules, linked via M1-G76, is attached to a target protein, regulating signaling and cell fate.
What genes are involved in protein linear polyubiquitination?
Key genes include HOIP, HOIL-1L, SHARPIN (forming LUBAC), NEMO, RIPK1, OTULIN, and CYLD.
How does linear polyubiquitination differ from other ubiquitination?
Unlike lysine-linked chains, linear polyubiquitination uses the N-terminal methionine of ubiquitin, creating a head-to-tail polymer with distinct signaling properties.
What is the role of linear polyubiquitination in NF-kappaB signaling?
It serves as a scaffold to recruit IKK complexes and activate NF-kappaB, controlling inflammation and immunity.
Which diseases are associated with defects in linear polyubiquitination?
Autoinflammatory diseases, cancer, Kawasaki disease, and infections like KSHV are linked to dysregulated linear polyubiquitination.
How can CRISPR be used to study linear polyubiquitination?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise manipulation of genes to study their function in the pathway.
What are the main enzymes that remove linear ubiquitin chains?
OTULIN and CYLD are deubiquitinases that specifically cleave M1-linked chains, negatively regulating the process.
Is linear polyubiquitination reversible?
Yes, it is reversible; deubiquitinases remove the chains to terminate signaling and prevent excessive inflammation.
What methods are used to detect linear polyubiquitination?
Immunoblotting with anti-linear ubiquitin antibodies, mass spectrometry, and immunofluorescence are common detection methods.
Why is linear polyubiquitination important for cell death?
It regulates apoptosis and necroptosis by modulating RIPK1 and NF-kappaB signaling, influencing cell survival decisions.
Conclusion
Protein linear polyubiquitination (GO:0097039) is a unique and critical post-translational modification that controls NF-kappaB signaling, immunity, and cell death. Its dysregulation is linked to a range of human diseases, making it an attractive target for therapeutic intervention. Advances in CRISPR-based models and screening technologies are accelerating our understanding of this pathway and its potential clinical applications.
References
- 1. Gao L et al.. 2023. The mechanism of linear ubiquitination in regulating cell death and correlative diseases.. Cell Death Dis 14(10):659 PMID: 37813853
- 2. Zein L et al.. 2025. Linear ubiquitination at damaged lysosomes induces local NFKB activation and controls cell survival.. Autophagy 21(5):1075-1095 PMID: 39744815
- 3. Hauenstein AV et al.. 2017. Evidence for M1-Linked Polyubiquitin-Mediated Conformational Change in NEMO.. J Mol Biol 429(24):3793-3800 PMID: 29111346
- 4. Iwai K et al.. 2009. Linear polyubiquitination: a new regulator of NF-kappaB activation.. EMBO Rep 10(7):706-13 PMID: 19543231
- 5. Ten Dijke P et al.. 2021. Fine-tuning ALK1 linear polyubiquitination to control angiogenesis.. Trends Cell Biol 31(9):705-707 PMID: 34330579
- 6. Luan Y et al.. 2024. Linear ubiquitination regulates the KSHV replication and transcription activator protein to control infection.. Nat Commun 15(1):5515 PMID: 38951495
- 7. Miao Y et al.. 2023. Linear ubiquitination improves NFAT1 protein stability and facilitates NFAT1 signalling in Kawasaki disease.. FEBS J 290(17):4224-4237 PMID: 36779231
- 8. Shimizu Y et al.. 2015. Linear ubiquitination in immunity.. Immunol Rev 266(1):190-207 PMID: 26085216
